- Home
- MGNI vs WGS Comparison
MGNI vs WGS Comparison
Compare MGNI & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNI
- WGS
- Stock Information
- Founded
- MGNI 2007
- WGS 2017
- Country
- MGNI United States
- WGS United States
- Employees
- MGNI N/A
- WGS N/A
- Industry
- MGNI Computer Software: Programming Data Processing
- WGS Retail: Computer Software & Peripheral Equipment
- Sector
- MGNI Technology
- WGS Technology
- Exchange
- MGNI Nasdaq
- WGS Nasdaq
- Market Cap
- MGNI 2.4B
- WGS 2.4B
- IPO Year
- MGNI N/A
- WGS N/A
- Fundamental
- Price
- MGNI $22.68
- WGS $108.35
- Analyst Decision
- MGNI Strong Buy
- WGS Strong Buy
- Analyst Count
- MGNI 12
- WGS 7
- Target Price
- MGNI $23.08
- WGS $99.29
- AVG Volume (30 Days)
- MGNI 2.9M
- WGS 1.0M
- Earning Date
- MGNI 08-06-2025
- WGS 07-29-2025
- Dividend Yield
- MGNI N/A
- WGS N/A
- EPS Growth
- MGNI N/A
- WGS N/A
- EPS
- MGNI 0.21
- WGS 0.05
- Revenue
- MGNI $674,622,000.00
- WGS $362,321,000.00
- Revenue This Year
- MGNI $0.43
- WGS $22.16
- Revenue Next Year
- MGNI $11.49
- WGS $19.63
- P/E Ratio
- MGNI $105.23
- WGS $2,235.73
- Revenue Growth
- MGNI 5.59
- WGS 48.70
- 52 Week Low
- MGNI $8.22
- WGS $25.32
- 52 Week High
- MGNI $25.27
- WGS $117.75
- Technical
- Relative Strength Index (RSI)
- MGNI 52.07
- WGS 73.52
- Support Level
- MGNI $21.40
- WGS $97.89
- Resistance Level
- MGNI $23.48
- WGS $107.31
- Average True Range (ATR)
- MGNI 0.84
- WGS 6.08
- MACD
- MGNI -0.36
- WGS 2.50
- Stochastic Oscillator
- MGNI 36.78
- WGS 99.91
About MGNI Magnite Inc.
Magnite Inc is one of the supply-side platform providers, or SSP, in online advertising. The firm generate its revenue from the programmatic sale of CTV ad inventory, from mobile online sites and apps, and the remaining from websites accessed via computer.
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.